11 results
8-K
EX-99.2
AKRO
Akero Therapeutics Inc
4 Mar 24
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
7:55am
and Hemostasis 1 2 3 Remained stable, including platelets, bilirubin, INR , MELD and CP score Progression to Cirrhosis Balanced across dose groups Bone Mineral
8-K
EX-99.2
AKRO
Akero Therapeutics Inc
10 Oct 23
Regulation FD Disclosure
8:04am
in systolic blood pressure were observed in the EFX dose groups. At Week 36, small reductions in bone mineral density were observed for the EFX dose … groups in the lumbar spine region (≤1%) and the femoral neck region (2-3%). Vital Signs and Bone Mineral Density
Statistically Significant Improvements
424B4
l3k0uz8wrfr
8 Jul 20
Prospectus supplement with pricing info
8:30pm
8-K
EX-99.2
ud6wn3
30 Jun 20
Akero Announces Strongly Positive Histological Data
4:16pm
8-K
EX-99.1
pa0 hhgwpcracf
30 Jun 20
Akero Announces Strongly Positive Histological Data
4:16pm
8-K
pt8ws3bivolgh5k
30 Jun 20
Akero Announces Strongly Positive Histological Data
4:16pm
D
avlirr12migyf34aw3l9
18 Dec 18
$45.5M in equity, sold $45.5M, 20 investors
5:20pm
- Prev
- 1
- Next